E Fund Management Co. Ltd. bought a new position in Anika Therapeutics, Inc. (NASDAQ:ANIK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,134 shares of the biotechnology company’s stock, valued at approximately $46,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. bought a new stake in shares of Anika Therapeutics in the 4th quarter worth approximately $27,000. Vantage Consulting Group Inc acquired a new stake in shares of Anika Therapeutics during the fourth quarter valued at approximately $27,000. Sowell Financial Services LLC raised its holdings in shares of Anika Therapeutics by 164.8% during the first quarter. Sowell Financial Services LLC now owns 1,017 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 633 shares during the period. US Bancorp DE raised its holdings in shares of Anika Therapeutics by 567.5% during the first quarter. US Bancorp DE now owns 1,335 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,135 shares during the period. Finally, Eaton Vance Management acquired a new stake in shares of Anika Therapeutics during the fourth quarter valued at approximately $242,000. Institutional investors and hedge funds own 92.51% of the company’s stock.
In related news, Director Raymond J. Land sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 12th. The shares were sold at an average price of $42.60, for a total transaction of $85,200.00. Following the transaction, the director now directly owns 7,953 shares of the company’s stock, valued at $338,797.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.09% of the company’s stock.
ANIK stock opened at $44.76 on Friday. Anika Therapeutics, Inc. has a 52-week low of $31.55 and a 52-week high of $48.37. The company’s 50 day moving average price is $42.54. The firm has a market capitalization of $644.14 million, a price-to-earnings ratio of -23.68, a P/E/G ratio of 24.26 and a beta of 1.21.
Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Wednesday, May 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.19. Anika Therapeutics had a negative net margin of 20.83% and a negative return on equity of 0.98%. The firm had revenue of $34.29 million for the quarter, compared to the consensus estimate of $32.39 million. As a group, equities research analysts predict that Anika Therapeutics, Inc. will post 0.19 EPS for the current fiscal year.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.
See Also: How is the LIBOR rate calculated?
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.